129 related articles for article (PubMed ID: 11467831)
1. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
2. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Rodríguez-González A; Ramírez de Molina A; Fernández F; Ramos MA; del Carmen Núñez M; Campos J; Lacal JC
Oncogene; 2003 Dec; 22(55):8803-12. PubMed ID: 14654777
[TBL] [Abstract][Full Text] [Related]
5. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
Rodríguez-González A; Ramirez de Molina A; Fernández F; Lacal JC
Oncogene; 2004 Oct; 23(50):8247-59. PubMed ID: 15378008
[TBL] [Abstract][Full Text] [Related]
6. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
Ramírez de Molina A; Gutiérrez R; Ramos MA; Silva JM; Silva J; Bonilla F; Sánchez JJ; Lacal JC
Oncogene; 2002 Jun; 21(27):4317-22. PubMed ID: 12082619
[TBL] [Abstract][Full Text] [Related]
7. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Ramírez de Molina A; Penalva V; Lucas L; Lacal JC
Oncogene; 2002 Jan; 21(6):937-46. PubMed ID: 11840339
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
Rodríguez-González A; Ramírez de Molina A; Benítez-Rajal J; Lacal JC
Prog Cell Cycle Res; 2003; 5():191-201. PubMed ID: 14593713
[TBL] [Abstract][Full Text] [Related]
9. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
10. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
Lucas L; Hernández-Alcoceba R; Penalva V; Lacal JC
Oncogene; 2001 Mar; 20(9):1110-7. PubMed ID: 11314048
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Ras farnesylation revert the increased resistance to oxidative stress in K-Ras transformed NIH 3T3 cells.
Santillo M; Mondola P; Gioielli A; Serù R; Iossa S; Annella T; Vitale M; Bifulco M
Biochem Biophys Res Commun; 1996 Dec; 229(3):739-45. PubMed ID: 8954966
[TBL] [Abstract][Full Text] [Related]
12. Choline kinase: an important target for cancer.
Janardhan S; Srivani P; Sastry GN
Curr Med Chem; 2006; 13(10):1169-86. PubMed ID: 16719778
[TBL] [Abstract][Full Text] [Related]
13. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies.
Podo F; Ferretti A; Knijn A; Zhang P; Ramoni C; Barletta B; Pini C; Baccarini S; Pulciani S
Anticancer Res; 1996; 16(3B):1399-412. PubMed ID: 8694508
[TBL] [Abstract][Full Text] [Related]
14. The choline kinase inhibitor hemicholinium-3 can inhibit mitogen-induced DNA synthesis independent of its effect on phosphocholine formation.
Crilly KS; Tomono M; Kiss Z
Arch Biochem Biophys; 1998 Apr; 352(1):137-43. PubMed ID: 9521826
[TBL] [Abstract][Full Text] [Related]
15. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
16. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.
Conejo-García A; Báñez-Coronel M; Sánchez-Martín RM; Rodríguez-González A; Ramos A; Ramírez de Molina A; Espinosa A; Gallo MA; Campos JM; Lacal JC
J Med Chem; 2004 Oct; 47(22):5433-40. PubMed ID: 15481981
[TBL] [Abstract][Full Text] [Related]
17. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.
Ramírez de Molina A; Gallego-Ortega D; Sarmentero J; Bañez-Coronel M; Martín-Cantalejo Y; Lacal JC
Cancer Res; 2005 Jul; 65(13):5647-53. PubMed ID: 15994937
[TBL] [Abstract][Full Text] [Related]
18. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras.
Gapuzan ME; Schmah O; Pollock AD; Hoffmann A; Gilmore TD
Oncogene; 2005 Sep; 24(43):6574-83. PubMed ID: 16027734
[TBL] [Abstract][Full Text] [Related]
19. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation.
Recktenwald CV; Kellner R; Lichtenfels R; Seliger B
Cancer Res; 2008 Dec; 68(24):10086-93. PubMed ID: 19074874
[TBL] [Abstract][Full Text] [Related]
20. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay.
Al-Saeedi F; Smith T; Welch A
Anticancer Res; 2007; 27(2):901-6. PubMed ID: 17465218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
